33 patents currently held
3 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
4 more records may belong here and await a decision; they are not counted.
The next term ends in Jan 2031. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Jan 2031
Next term end
15
Patent families
When these terms end
Held patents by the year their term ends
notable patents
all others
Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Jul 2031 · High confidence
Also notable
Ends Feb 2031 · High confidence
Also notable
Ends Feb 2031 · High confidence
Also notable
Ends Jul 2033 · High confidence
Also notable
Ends Jul 2033 · High confidence
Also notable
Ends Nov 2032 · High confidence
Also notable
Ends Feb 2031 · High confidence
Also notable
Ends Sep 2035 · High confidence
Immunocompatible Amniotic Membrane Products
US 10,272,116
Cited by 31 later US patents, top 10% of utility patents granted in 2019 in our data, and renewed at 2 of 3 maintenance windows. Protection runs to 2031.
Methods of Manufacture of Therapeutic Products Comprising Vitalized Placental Dispersions
US 9,956,248
Cited by 45 later US patents, top 10% of utility patents granted in 2018 in our data, and renewed at every maintenance window due so far. Protection runs to 2031.
Immunocompatible Chorionic Membrane Products
US 11,590,172
Cited by 9 later US patents, top 10% of utility patents granted in 2023 in our data. Protection runs to 2031. A terminal disclaimer caps this term to an earlier patent's.
Methods of Manufacturing Cartilage Products
US 11,406,735
Cited by 22 later US patents, top 5% of utility patents granted in 2022 in our data. Protection runs to 2033.
Disrupted Cartilage Products
US 11,413,373
Cited by 21 later US patents, top 5% of utility patents granted in 2022 in our data. Protection runs to 2033.
Methods of Manufacture of Immunocompatible Chorionic Membrane Products
US 10,258,650
Cited by 24 later US patents, top 10% of utility patents granted in 2019 in our data, and renewed at 2 of 3 maintenance windows. Protection runs to 2032.
Methods of Manufacture of Immunocompatible Amniotic Membrane Products
US 10,576,104
Cited by 33 later US patents, top 10% of utility patents granted in 2020 in our data. Protection runs to 2031. A terminal disclaimer caps this term to an earlier patent's.
Bone Repair Product and Methods of Use Thereof
US 10,828,395
Cited by 10 later US patents, top 25% of utility patents granted in 2020 in our data. Protection runs to 2035.
Formerly held, still cited
Notable
Ends Jan 2027 · High confidence
Cited by 32 later US patents, top 25% of utility patents granted in 2013 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2027.
now held by Mesoblast International Sàrl
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 2 fees due Sep 3 to 30, 2027 · next Sep 3
- 1 fee due Oct 21, 2027The maintenance fee for Umbilical Tissue Compositions and Methods of Use (US 10,624,931) comes due Oct 21, 2027. Unpaid by Apr 21, 2028, it lapses early.
- 1 fee due Nov 12, 2027The maintenance fee for Methods of Manufacture of Therapeutic Products Comprising Vitalized Placental Dispersions (US 10,646,519) comes due Nov 12, 2027. Unpaid by May 12, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
What they patent
The largest of its 15 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
| Biological Product Support Element | 4 in force | to Mar 2034 |
| Methods of Manufacture of Therapeutic Products Comprising Vitalized Placental Dispersions | 4 in force | to Apr 2031 |
| Bone Repair Product and Methods of Use Thereof | 3 in force | to Sep 2035 |
| Methods of Manufacture of Immunocompatible Chorionic Membrane Products | 3 in force | to Nov 2032 |
| Immunocompatible Chorionic Membrane Products | 3 in force | to Oct 2031 |
| Human Tissue Derived Compositions and Uses Thereof | 2 in force | to Jun 2037 |
| Umbilical Tissue Compositions and Methods of Use | 2 in force | to Sep 2036 |
| Support and Packaging for Membranes | 2 in force | to Jan 2036 |
| Methods of Manufacturing Cartilage Products | 2 in force | to Jul 2033 |
| Immunocompatible Amniotic Membrane Products | 2 in force | to Jul 2031 |
| Methods of Manufacture of Immunocompatible Amniotic Membrane Products | 2 in force | to Feb 2031 |
| Porated Cartilage Products | 1 in force | to Jul 2033 |
| Disrupted Cartilage Products | 1 in force | to Jul 2033 |
| Therapeutic Products Comprising Vitalized Placental Dispersions | 1 in force | to Feb 2031 |
Patents held now
Soonest term end first.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US D776,823 | Biological Product Support Element In force · High confidence | In force | High confidence | |
| US 9,956,248 | Methods of Manufacture of Therapeutic Products Comprising Vitalized Placental Dispersions In force · High confidence | In force | High confidence | |
| US 10,576,104 | Methods of Manufacture of Immunocompatible Amniotic Membrane Products In force · High confidence | In force | High confidence | |
| US 11,207,353 | Immunocompatible Amniotic Membrane Products In force · High confidence | In force | High confidence | |
| US 11,510,947 | Methods of Manufacture of Immunocompatible Amniotic Membrane Products In force · High confidence | In force | High confidence | |
| US 11,590,172 | Immunocompatible Chorionic Membrane Products In force · High confidence | In force | High confidence | |
| US 11,590,173 | Methods of Manufacture of Therapeutic Products Comprising Vitalized Placental Dispersions In force · High confidence | In force | High confidence | |
| US 11,638,725 | Methods of Manufacture of Immunocompatible Chorionic Membrane Products In force · High confidence | In force | High confidence | |
| US 11,986,498 | Therapeutic Products Comprising Vitalized Placental Dispersions In force · High confidence | In force | High confidence | |
| US 12,109,241 | Methods of Manufacture of Immunocompatible Chorionic Membrane Products In force · High confidence | In force | High confidence |
Also on record, not counted in the 33: 3 patents in force now held by others · 17 patents ended · 20 applications pending · 59 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.